These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27770740)

  • 21. [Higher probability of remission with escitalopram in comparison to citalopram].
    Linné AB; Hallberg I
    Lakartidningen; 2009 Apr 28-May 12; 106(18-19):1292; discussion 1292-3. PubMed ID: 19537504
    [No Abstract]   [Full Text] [Related]  

  • 22. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Escitalopram in the treatment of major depressive disorder: a meta-analysis.
    Kennedy SH; Andersen HF; Thase ME
    Curr Med Res Opin; 2009 Jan; 25(1):161-75. PubMed ID: 19210149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. fMRI response to negative words and SSRI treatment outcome in major depressive disorder: a preliminary study.
    Miller JM; Schneck N; Siegle GJ; Chen Y; Ogden RT; Kikuchi T; Oquendo MA; Mann JJ; Parsey RV
    Psychiatry Res; 2013 Dec; 214(3):296-305. PubMed ID: 24446548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.
    Lepola U; Wade A; Andersen HF
    Int Clin Psychopharmacol; 2004 May; 19(3):149-55. PubMed ID: 15107657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of antidepressant treatment on resting-state functional brain networks in patients with major depressive disorder.
    Wang L; Xia M; Li K; Zeng Y; Su Y; Dai W; Zhang Q; Jin Z; Mitchell PB; Yu X; He Y; Si T
    Hum Brain Mapp; 2015 Feb; 36(2):768-78. PubMed ID: 25332057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder.
    Brown ES; Sayed N; Van Enkevort E; Kulikova A; Nakamura A; Khan DA; Ivleva EI; Sunderajan P; Bender BG; Holmes T
    J Allergy Clin Immunol Pract; 2018; 6(5):1604-1612. PubMed ID: 29409976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
    J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication.
    Muhonen LH; Lahti J; Sinclair D; Lönnqvist J; Alho H
    Subst Abuse Treat Prev Policy; 2008 Oct; 3():20. PubMed ID: 18834506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mapping the effect of escitalopram treatment on amplitude of low-frequency fluctuations in patients with depression: a resting-state fMRI study.
    Wang L; Li X; Li K; Su Y; Zeng Y; Zhang Q; Wang G; Jin Z; Kong Q; Si T
    Metab Brain Dis; 2017 Feb; 32(1):147-154. PubMed ID: 27524655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.
    Kornstein SG; Bose A; Li D; Saikali KG; Gandhi C
    J Clin Psychiatry; 2006 Nov; 67(11):1767-75. PubMed ID: 17196058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Escitalopram.
    Aronson S; Delgado P
    Drugs Today (Barc); 2004 Feb; 40(2):121-31. PubMed ID: 15045034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
    J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
    Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
    Trials; 2011 Jan; 12():4. PubMed ID: 21208417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
    Burke WJ; Gergel I; Bose A
    J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
    Lepola UM; Loft H; Reines EH
    Int Clin Psychopharmacol; 2003 Jul; 18(4):211-7. PubMed ID: 12817155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
    Llorca PM; Fernandez JL
    Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.